New online! MicroRNA-132 inhibitor is well-tolerated in patients with MI and LV dysfunction #CardioSky
dlvr.it
Nature Reviews Cardiology, Published online: 27 May 2026; doi:10.1038/s41569-026-01308-5In the randomized, phase II HF-REVERT trial, the miR-132 inhibitor CDR132L was well-tolerated and showed pharmacodynamic target engagement in patients with myocardial infarction and reduced left ventricular ejection fraction, but did not improve ventricular remodelling compared with placebo.
